Early Invasive Heart Procedures Offer No Survival Advantage Over Medication in Stable Disease

For patients diagnosed with stable coronary artery disease, the immediate clinical instinct following an abnormal stress test is often to mechanically clear the blockage. Physicians and patients alike have long operated under the intuitive assumption that opening narrowed blood vessels with stents or bypass surgery will inherently prevent future fatal heart attacks.[2][3]

However, a comprehensive international study tracking more than 5,000 patients for up to 13 years has definitively challenged that deeply ingrained clinical reflex. The ISCHEMIA-EXTEND trial demonstrates that performing early invasive procedures does not help patients live longer than a strategy based entirely on intensive medication and lifestyle modifications.[1][2]

The findings, presented on November 7, 2026, at the American Heart Association’s Scientific Sessions in Chicago and published simultaneously in the Journal of the American Medical Association, represent one of the longest and most rigorous follow-up investigations in modern cardiovascular medicine.[1][2]

Researchers from NYU Langone Health and an international consortium of investigators tracked 5,179 participants across 320 hospitals in 37 countries. They compared an initial invasive strategy against a conservative, medication-first approach where surgical procedures were strictly reserved for patients whose symptoms worsened or who subsequently suffered a heart attack.[1][2][4]

After nearly a decade of median follow-up, the mortality difference between the two groups was statistically insignificant. The invasive approach was associated with a 26 percent chance of all-cause mortality, compared with a 27 percent chance for the conservative medical approach.[2]

"Our analyses make clear that while managing stable coronary artery disease with early heart procedures helps relieve chest pain and improves quality of life in those with chest pain, it is unlikely to help patients live longer," said Dr. Judith S. Hochman, the Harold Snyder Family Professor of Cardiology at NYU Grossman School of Medicine and the study's co-lead author.[2]

Understanding the Trial Design

The original International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial enrolled patients between 2012 and 2018. Participants had a median age of 64 years, 23 percent were female, and 42 percent had a concurrent diagnosis of diabetes.[1][5]

All participants exhibited moderate to severe ischemia on stress testing, meaning their heart muscle was being deprived of adequate blood flow during physical exertion. Crucially, these patients had stable chronic coronary disease, characterized by fatty plaque buildup that narrows arteries but does not cause the sudden, complete vessel occlusion that triggers an acute myocardial infarction.[1][2]

Every patient in the trial received aggressive, guideline-directed medical therapy. This baseline care included the optimization of blood pressure and the administration of high-intensity statins to control cholesterol, alongside structured clinical counseling on diet, smoking cessation, and daily physical activity.[1][4]

The invasive group underwent routine cardiac catheterization followed by revascularization—either via percutaneous coronary intervention with stents or surgical coronary artery bypass grafting—shortly after their randomization. The conservative group continued their medical therapy and only crossed over to invasive procedures if their medical management failed to control their angina or if they experienced an acute cardiac event.[1][5]

The Long-Term Survival Data

When the initial ISCHEMIA results were published in 2020, they showed that the invasive strategy provided durable improvements in angina control but yielded no short-term reduction in major adverse cardiac events or overall mortality.[2][4]

However, cardiovascular mortality curves in clinical trials can sometimes take years to separate. Researchers launched the ISCHEMIA-EXTEND phase to determine if a survival advantage for the invasive group would emerge over a longer time horizon, similar to the delayed mortality benefits observed in other historic surgical trials.[5]

The extended follow-up effort achieved an extraordinary 96 percent vital status ascertainment rate, utilizing direct patient contact and national medical registries to track outcomes across the globe. Over the extended observation period, investigators recorded a total of 1,071 deaths among the study cohort.[2]

The data confirmed that the initial equivalence in survival was permanent. While the invasive strategy showed a slight reduction in cardiovascular-specific deaths, this was entirely offset by a corresponding increase in non-cardiovascular mortality, leaving the overall survival rate functionally identical at 26 percent versus 27 percent.[1][5]

Quality of Life Versus Longevity

The absence of a survival benefit fundamentally shifts the clinical conversation from preventing death to managing daily symptoms. For patients experiencing frequent or debilitating angina that limits their physical activity, stents and bypass surgeries remain highly effective tools for restoring quality of life.[2][3]

"Our results highlight the need for thoughtful discussions between patients with stable heart disease and their healthcare providers about goals and trade-offs," said Dr. Rebecca Anthopolos, an assistant professor in NYU Grossman School of Medicine's Department of Population Health and study co-lead author.[2]

"For people with chest pain, early procedures relieve symptoms and improve daily life, but they also carry risks and should be weighed against evidence that taking modern medicines and following healthy habits leads to similar survival," Anthopolos explained.[2]

Redefining Clinical Practice

Cardiologists emphasize that these findings do not apply to patients experiencing an active heart attack or those with unstable, rapidly worsening symptoms. In acute coronary syndromes, emergency revascularization remains a critical, life-saving intervention that dramatically reduces mortality and limits permanent heart muscle damage.[2]

For the stable patient, however, the ISCHEMIA-EXTEND data empowers a more measured, conservative approach. A patient who receives an abnormal stress test result but experiences minimal daily symptoms can safely opt to optimize their medications without rushing into the catheterization laboratory.[3][4]

This paradigm shift has profound implications for global healthcare systems and resource allocation. Routine invasive procedures carry inherent procedural risks, require significant recovery time, and impose substantial financial costs on both patients and hospitals.[3]

AI

By reserving these mechanical interventions strictly for symptom relief rather than survival, health systems can redirect critical resources while sparing asymptomatic patients from unnecessary surgical risks and prolonged hospital stays.[3]

Unanswered Questions and Next Steps

While the survival question appears settled, the extended follow-up phase did not track nonfatal heart attacks, repeat hospitalizations, or long-term quality of life metrics beyond the initial trial period. This limitation leaves some uncertainty regarding the broader morbidity burden experienced by the two groups over the full 13-year window.[2]

Additionally, a companion analysis known as ISCHEMIA-CKD EXTEND is currently evaluating these same strategies in patients with advanced chronic kidney disease. This population carries a uniquely high burden of cardiovascular risk but is frequently excluded from major cardiology trials, making the forthcoming data highly anticipated.[5]

As cardiovascular medicine continues to evolve, the ISCHEMIA-EXTEND trial stands as a testament to the efficacy of modern pharmacotherapy. It reassures patients that a prescription pad and a commitment to lifestyle changes can be just as powerful as a surgical scalpel in securing their long-term survival.[2][3]